Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
I'm PortAI, I can summarize articles.
Ram Selvaraju from H.C. Wainwright has reiterated a Buy rating for Entrada Therapeutics Inc. with a price target of $20. This rating is supported by the company's advancing clinical pipeline, particularly in Duchenne muscular dystrophy (DMD) and the partnered DM1 program. Key upcoming trials, including ELEVATE-44-201, are expected to drive value. Additionally, Entrada's strategic focus on ophthalmology and metabolic diseases, with new ocular programs targeting inherited retinal disorders, enhances its growth potential. Overall, the combination of clinical data and expanding franchises supports the positive outlook.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments